On Apr. 16, 2019, Sinovac Biotech announced that the positive results from the Company’s Phase III clinical study of a Sabin strain-based inactivated polio vaccine (sIPV) developed by Sinovac were published in the Journal of Infectious Disease.

With Sinovac’s sIPV, efficacy was maintained while common risks associated with legacy vaccines can be mitigated. In comparison to oral polio vaccine (OPV), inactivated polio vaccine (IPV) contains no live virus and thus carries no risk of vaccine-derived poliovirus (VDPV) emergence or vaccine-associated paralytic polio.